Can ovaries help older female mice live longer?

HERETICAL: The graft's survival benefit requires controlled death and clearance of young ovarian somatic cells. Recipient macrophages engulf apoptotic donor cells and initiate sustained resolution of damaging inflammation; continued donor endocrine secretion is unnecessary. Germ-cell depletion increases the accessible somatic apoptotic substrate. Preventing donor apoptosis should therefore weaken benefit despite improving graft viability. This mechanism stabilizes SPV_11 by reducing inflammatory mortality and functional deterioration.

Apoptotic cells reproduce the survival and functional benefit, whereas apoptosis-resistant viable grafts lose it. A recipient-phagocyte-specific efferocytosis perturbation abolishes benefit, with the corresponding sham-by-perturbation controls distinguishing general toxicity. Antigen-specific T-cell transfer does not reproduce protection.

A functioning young ovarian network rejects a single extreme input but responds to concordant distributed inputs. Selectively disabling input sensing while preserving basal secretion abolishes this pattern. Only after demonstrating that signature should grafted animals test whether sensing-competent grafts outperform sensing-disabled grafts and a matched open-loop secretome replay in survival and function.

Ovarian graft antigens could trigger tumor immunity and extend survival predicts instead: Protection transfers with purified recipient tumor-reactive T cells, but not with cell-free serum after removal of donor-derived material. Removing an experimentally identified shared antigen from otherwise matched donor tissue, or selectively interrupting its cross-presentation, eliminates the survival advantage. Benefit is concentrated in reduced antigen-positive lethal tumors; broad nonmalignant functional recovery is not required. Equal apoptosis and clearance of antigen-negative donor cells fail to reproduce protection.

Small genetic messages from young ovarian support cells may suppress mobile genetic elements predicts instead: Identify a donor-derived small RNA that reaches recipient Argonaute complexes at an effective concentration. Selectively remove that RNA from donor cells while preserving viability, steroids, apoptosis and major protein secretion. Loss of recipient retroelement suppression and survival benefit, followed by rescue with sequence-matched RNA but not a binding-defective version, supports this IH. Recipient retroelement reporters with resistant target sequences should escape suppression despite otherwise intact graft signaling.

CROSS-DOMAIN TRANSFER: Young ovarian somatic networks stabilize systemic injury responses by integrating redundant tissue-distress signals and rejecting isolated extreme signals. Reciprocal activin-family and cytokine communication makes the graft a participating node in a distributed estimate of inflammatory burden, with follistatin as one candidate corrective output. A viable adaptive network therefore protects when a fixed steroid profile or fixed secretome cannot. The causal property is resistance to misleading individual inputs, not circadian phase alignment. This mechanism stabilizes SPV_11 by preventing disproportionate systemic responses to localized injury.

A functioning young ovarian network rejects a single extreme input but responds to concordant distributed inputs. Selectively disabling input sensing while preserving basal secretion abolishes this pattern. Only after demonstrating that signature should grafted animals test whether sensing-competent grafts outperform sensing-disabled grafts and a matched open-loop secretome replay in survival and function.

Apoptotic cells reproduce the survival and functional benefit, whereas apoptosis-resistant viable grafts lose it. A recipient-phagocyte-specific efferocytosis perturbation abolishes benefit, with the corresponding sham-by-perturbation controls distinguishing general toxicity. Antigen-specific T-cell transfer does not reproduce protection.

Ovarian graft antigens could trigger tumor immunity and extend survival predicts instead: Protection transfers with purified recipient tumor-reactive T cells, but not with cell-free serum after removal of donor-derived material. Removing an experimentally identified shared antigen from otherwise matched donor tissue, or selectively interrupting its cross-presentation, eliminates the survival advantage. Benefit is concentrated in reduced antigen-positive lethal tumors; broad nonmalignant functional recovery is not required. Equal apoptosis and clearance of antigen-negative donor cells fail to reproduce protection.

Small genetic messages from young ovarian support cells may suppress mobile genetic elements predicts instead: Identify a donor-derived small RNA that reaches recipient Argonaute complexes at an effective concentration. Selectively remove that RNA from donor cells while preserving viability, steroids, apoptosis and major protein secretion. Loss of recipient retroelement suppression and survival benefit, followed by rescue with sequence-matched RNA but not a binding-defective version, supports this IH. Recipient retroelement reporters with resistant target sequences should escape suppression despite otherwise intact graft signaling.

SCOUT 1, from cancer vaccinology: Germ-cell-depleted young ovarian somatic tissue exposes antigens shared with incipient recipient tumors. Cross-presentation generates tumor-reactive adaptive immunity, lowering lethal cancer incidence and producing a real survival advantage without generalized rejuvenation. Germ-cell depletion changes antigen accessibility rather than restoring reproductive function. This mechanism stabilizes SPV_11 through prevention of a specific competing cause of death.

Removing an experimentally identified shared antigen from otherwise matched donor tissue, or selectively interrupting its cross-presentation, eliminates the survival advantage. Benefit is concentrated in reduced antigen-positive lethal tumors; broad nonmalignant functional recovery is not required. Equal apoptosis and clearance of antigen-negative donor cells fail to reproduce protection.

Apoptotic cells reproduce the survival and functional benefit, whereas apoptosis-resistant viable grafts lose it. A recipient-phagocyte-specific efferocytosis perturbation abolishes benefit, with the corresponding sham-by-perturbation controls distinguishing general toxicity. Antigen-specific T-cell transfer does not reproduce protection.

Young ovarian networks may limit systemic injury by rejecting isolated extreme distress signals predicts instead: In a perfused multi-tissue system, perturb one communication node versus several independently connected nodes while matching total cytokine exposure. A functioning young ovarian network rejects a single extreme input but responds to concordant distributed inputs. Selectively disabling input sensing while preserving basal secretion abolishes this pattern. Only after demonstrating that signature should grafted animals test whether sensing-competent grafts outperform sensing-disabled grafts and a matched open-loop secretome replay in survival and function.

Small genetic messages from young ovarian support cells may suppress mobile genetic elements predicts instead: Identify a donor-derived small RNA that reaches recipient Argonaute complexes at an effective concentration. Selectively remove that RNA from donor cells while preserving viability, steroids, apoptosis and major protein secretion. Loss of recipient retroelement suppression and survival benefit, followed by rescue with sequence-matched RNA but not a binding-defective version, supports this IH. Recipient retroelement reporters with resistant target sequences should escape suppression despite otherwise intact graft signaling.

SCOUT 2, from retrovirology and genome defense: Young ovarian somatic cells export small RNAs that suppress active retroelements in recipient tissues. Sequence-specific restriction reduces retroelement-derived nucleic acids, innate immune activation and subsequent injury. Germ cells are unnecessary because the relevant restriction program resides in somatic cells. miR-128 is a test candidate rather than an established ovarian mediator. This mechanism stabilizes SPV_11 through continued suppression of a molecular damage source.

Selectively remove that RNA from donor cells while preserving viability, steroids, apoptosis and major protein secretion. Loss of recipient retroelement suppression and survival benefit, followed by rescue with sequence-matched RNA but not a binding-defective version, supports this IH. Recipient retroelement reporters with resistant target sequences should escape suppression despite otherwise intact graft signaling.

Apoptotic cells reproduce the survival and functional benefit, whereas apoptosis-resistant viable grafts lose it. A recipient-phagocyte-specific efferocytosis perturbation abolishes benefit, with the corresponding sham-by-perturbation controls distinguishing general toxicity. Antigen-specific T-cell transfer does not reproduce protection.

Young ovarian networks may limit systemic injury by rejecting isolated extreme distress signals predicts instead: In a perfused multi-tissue system, perturb one communication node versus several independently connected nodes while matching total cytokine exposure. A functioning young ovarian network rejects a single extreme input but responds to concordant distributed inputs. Selectively disabling input sensing while preserving basal secretion abolishes this pattern. Only after demonstrating that signature should grafted animals test whether sensing-competent grafts outperform sensing-disabled grafts and a matched open-loop secretome replay in survival and function.

Ovarian graft antigens could trigger tumor immunity and extend survival predicts instead: Protection transfers with purified recipient tumor-reactive T cells, but not with cell-free serum after removal of donor-derived material. Removing an experimentally identified shared antigen from otherwise matched donor tissue, or selectively interrupting its cross-presentation, eliminates the survival advantage. Benefit is concentrated in reduced antigen-positive lethal tumors; broad nonmalignant functional recovery is not required. Equal apoptosis and clearance of antigen-negative donor cells fail to reproduce protection.